Adult Onset Still’s Disease (AOSD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034
Adult Onset Still’s Disease (AOSD) Market Outlook
Thelansis’s “Adult Onset Still’s
Disease (AOSD) Market Outlook, Epidemiology, Competitive Landscape, and Market
Forecast Report – 2024 To 2034" covers disease overview, epidemiology,
drug utilization, prescription share analysis, competitive landscape, clinical
practice, regulatory landscape, patient share, market uptake, market forecast,
and key market insights under the potential Adult Onset Still’s Disease (AOSD) treatment modalities options for eight major
markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Adult
Onset Still’s Disease (AOSD) Overview
Adult
onset Still’s Disease (AoSD) is a rare systemic autoinflammatory disease
characterized by arthritis, spiking fever, skin rash, and elevated ferritin
levels. Fever is a cardinal symptom in AoSD and occurs in 60 to 100% of cases.
Patients typically report two fever spikes daily, one in the morning and one in
the evening, usually >39 ◦C. In 60 to 80% of patients, a macular or
maculopapular evanescent salmon-pink skin rash on the proximal limbs and trunk
accompanies high fever. Arthralgia is the symptom that is observed in 70 to
100% of patients, often accompanied by polyarthritis involving small joints,
imitating rheumatoid arthritis. Some patients with chronic articular AoSD show
severe osteodestructive features, which cause ankyloses and functional disability.
Leukopenia is related to an unfortunate course of disease with complications
such as reactive haemophagocytic lymphohistiocytosis or thrombotic angiopathy.
Geography
coverage:
G8 (United States,
EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven
by robust research, including:
- In-depth interviews with leading
KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR
datasets
- Secondary research (e.g.,
peer-reviewed journal articles, third-party research databases)
Deliverables
format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS
Excel-based automated dashboard)
- Epidemiology (MS Excel; interactive
tool)
- Executive Insights (PowerPoint
presentation)
- Others: regular updates,
customizations, consultant support
*As per
Thelansis’s policy, we ensure that we include all the recent updates before
releasing the report content and market model.
Salient
features of Market Forecast model:
- 10-year market forecast (2024–2034)
- Bottom-up patient-based market
forecasts validated through the top-down sales methodology
- Covers clinically and
commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and
patient share projections
- Utilizes our proprietary Epilansis and Analog tool
(e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources
& assumptions
- Graphical and tabular outputs
- Users can customize the model based
on requirements
Key business
questions answered:
- How can drug development and
lifecycle management strategies be optimized across G8 markets (US, EU5,
Japan, and China)?
- How large is the patient population
in terms of incidence, prevalence, segments, and those receiving drug
treatments?
- What is the 10-year market outlook
for sales and patient share?
- Which events will have the greatest
impact on the market’s trajectory?
- What insights do interviewed experts
provide on current and emerging treatments?
- Which pipeline products show the
most promise, and what is their potential for launch and future
positioning?
- What are the key unmet needs and KOL
expectations for target profiles?
- What key regulatory and payer
requirements must be met to secure drug approval and favorable market
access?
- and more…
Comments
Post a Comment